Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

December 22, 2020

Study Completion Date

June 28, 2021

Conditions
Mild to Moderate Alzheimer's Disease
Interventions
DRUG

AR1001

AR1001 Active Oral Tablet

DRUG

Placebo

Placebo Oral Tablet

Trial Locations (21)

29485

Palmetto Clinical Research, Summerville

30033

NeuroStudies, LLC, Decatur

32751

Meridien - Maitland, Maitland

32806

Accelerated Enrollment Solutions (AES), Orlando

33157

IMIC, Inc, Palmetto Bay

33176

The Neurology Research Group, Miami

33634

Meridien Research - Tampa, Tampa

33709

Meridien Research - St Petersburg, St. Petersburg

33805

Meridien Research, Lakeland

34609

Meridien Research - Spring Hill, Spring Hill

44122

Rapid Medical Research, Beachwood

73112

Lynn Health Science Institute, Oklahoma City

76550

FMC Science, Lampasas

78613

Advanced Clinical Research - Cedar Park, Cedar Park

83642

Advanced Clinical Research, Meridian

84088

Advanced Clinical Research, Inc., West Jordan

89106

Wake Research - CRCNV, Las Vegas

92220

Advanced Clinical Research, Inc., Banning

92705

Syrentis Clinical Research, Santa Ana

95821

Northern California Research, Sacramento

99202

Kingfisher Cooperative, LLC, Spokane

All Listed Sponsors
lead

AriBio Co., Ltd.

INDUSTRY

NCT03625622 - Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter